CHOLERA VACCINE MARKET TOP KEY PLAYERS: VALNEVA SE, EMERGENT BIOSOLUTIONS, INC. (PAXVAX, INC.), ASTELLAS PHARMA, INC., SANOFI (SHANTHA BIOTECHNICS PRIVATE LIMITED), EUBIOLOGICS CO., LTD., JOHNSON & JOHNSON (CRUCELL), CELLDEX THERAPEUTICS, INC.

A fresh report titled “Cholera Vaccine Market” has been presented by KD market insights. It evaluates the key market trends, advantages, and factors that are pushing the overall growth of the market. The report also analyzes the different segments along with major geographies that have more demand for Cholera Vaccine Market. The competition analysis is also a major part of the report.

The global cholera vaccine market generated $65 million in 2017, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025.

Request for Sample @ https://www.kdmarketinsights.com/sample/3400

Cholera is an acute intestinal infection that causes rapidly dehydrating diarrheal disease, which is caused by toxigenic serogroups of the bacterium Vibrio cholera. The disease is closely associated with poverty, poor sanitation, and lack of clean drinking water. Historically, devastating outbreaks of cholera resulted in millions of cases and hundreds of thousands of deaths. Currently, cholera remains an important public health problem in many countries, occurring as an endemic disease in some regions and causing major epidemics in some low- and middle-income countries (LMICs). The vaccine is used to control cholera and is mainly recommended for travelers and the people living in cholera-affected region.

There is an increase in the demand for cholera vaccine due to lack of proper sanitation & consumption of contaminated food and growth in the awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players.

The global cholera vaccine market is segmented based on product, end user, and region. Based on product, the market is segmented into Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-Plus, and others. Depending on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits For Cholera Vaccine Market:

– This report provides a detailed quantitative analysis of the current market trends and future estimations from 2018 to 2025, which assists to identify the prevailing market opportunities.
– An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
– A comprehensive analysis of the factors that drive and restrain the growth of the global cholera vaccine market is provided.
– An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

Cholera Vaccine Key Market Segments:

By Product
– Dukoral
– Shanchol
– Vaxchora
– Euvichol & Euvichol-Plus
– Others

By End User
– Hospitals & Clinics
– Research & Academic Laboratories
– Others

By Region
North America
– U.S.
– Canada
– Mexico
Europe
– Germany
– France
– UK
– Italy
– Sweden
– Rest of Europe
Asia-Pacific
– Australia
– Japan
– India
– Vietnam
– Rest of Asia-Pacific
LAMEA
– Nigeria
– Malawi
– Zambia
– Rest of LAMEA

Key Market Players
– Valneva SE
– Emergent BioSolutions, Inc. (PaxVax, Inc.)
– Astellas Pharma, Inc.
– Sanofi (Shantha Biotechnics Private Limited)
– Eubiologics Co., Ltd.
– Johnson & Johnson (Crucell)
– Celldex Therapeutics, Inc.

The other players in the value chain include (profiles not included in the report):
– Merck & Co., Inc.
– GlaxoSmithKline plc.

Browse Full Report With TOC@ https://www.kdmarketinsights.com/product/cholera-vaccine-market-amr

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top Player Positioning, 2017
3.4. Porters five forces analysis
3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Lack of proper sanitation and consumption of contaminated food
3.5.1.2. Rise in awareness about cholera preventive care
3.5.1.3. Development of novel approaches for new cholera vaccine

3.5.2. Restraints

3.5.2.1. Risk of adverse effects
3.5.2.2. The time taken for the regulatory approval

3.5.3. Opportunities

3.5.3.1. High growth opportunities in untapped markets

CHAPTER 4: CHOLERA VACCINE MARKET, BY PRODUCT

4.1. Overview

4.1.1. Market size and forecast

4.2. Dukoral

4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Shanchol

4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Vaxchora

4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Euvichol & Euvichol-Plus

4.5.1. Key market trends and growth opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Others

4.6.1. Key market trends and growth opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: CHOLERA VACCINE MARKET, BY END USER

5.1. Overview

5.1.1. Market size and forecast

5.2. Hospitals & Clinics

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Research & Academic Laboratories

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Others

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: CHOLERA VACCINE MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends and opportunities
6.2.2. North America cholera vaccine market, by country

6.2.2.1. U.S. cholera vaccine market by product
6.2.2.2. U.S. cholera vaccine market by end user
6.2.2.3. Canada cholera vaccine market by product
6.2.2.4. Canada cholera vaccine market by end user
6.2.2.5. Mexico cholera vaccine market by product
6.2.2.6. Mexico cholera vaccine market by end user

6.2.3. North America cholera vaccine market, by product
6.2.4. North America cholera vaccine market, by end user

6.3. Europe

6.3.1. Key market trends and opportunities
6.3.2. Europe cholera vaccine market, by country

6.3.2.1. Germany cholera vaccine market by product
6.3.2.2. Germany cholera vaccine market by end user
6.3.2.3. France cholera vaccine market by product
6.3.2.4. France cholera vaccine market by end user
6.3.2.5. UK cholera vaccine market by product
6.3.2.6. UK cholera vaccine market by end user
6.3.2.7. Italy cholera vaccine market by product
6.3.2.8. Italy cholera vaccine market by end user
6.3.2.9. Sweden cholera vaccine market by product
6.3.2.10. Sweden cholera vaccine market by end user
6.3.2.11. Rest of Europe cholera vaccine market by product
6.3.2.12. Rest of Europe cholera vaccine market by end user

6.3.3. Europe cholera vaccine market, by product
6.3.4. Europe cholera vaccine market, by end user

6.4. Asia-Pacific

6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific cholera vaccine market, by country

6.4.2.1. Australia cholera vaccine market by product
6.4.2.2. Australia cholera vaccine market by end user
6.4.2.3. Japan cholera vaccine market by product
6.4.2.4. Japan cholera vaccine market by end user
6.4.2.5. India cholera vaccine market by product
6.4.2.6. India cholera vaccine market by end user
6.4.2.7. Vietnam cholera vaccine market by product
6.4.2.8. Vietnam cholera vaccine market by end user
6.4.2.9. Rest of Asia-Pacific cholera vaccine market by product
6.4.2.10. Rest of Asia-Pacific cholera vaccine market by end user

6.4.3. Asia-Pacific cholera vaccine market, by product
6.4.4. Asia-Pacific cholera vaccine market, by end user

6.5. LAMEA

6.5.1. Key market trends and opportunities
6.5.2. LAMEA cholera vaccine market, by country

6.5.2.1. Nigeria cholera vaccine market by product
6.5.2.2. Nigeria cholera vaccine market by end user
6.5.2.3. Malawi cholera vaccine market by product
6.5.2.4. Malawi cholera vaccine market by end user
6.5.2.5. Zambia cholera vaccine market by product
6.5.2.6. Zambia cholera vaccine market by end user
6.5.2.7. Rest of LAMEA cholera vaccine market by product
6.5.2.8. Rest of LAMEA cholera vaccine market by end user

6.5.3. LAMEA cholera vaccine market, by product
6.5.4. LAMEA cholera vaccine market, by end user

Continue…

Check for Discount @ https://www.kdmarketinsights.com/discount/3400

Contact Us

KD Market Insights

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: sales@kdmarketinsights.com

Website: www.kdmarketinsights.com

About KD Market Insights

KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights.

Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market.

This release was published on openPR.